

開發新穎藥物用以治療 惡性神經膠母細胞瘤的新策略

主要領域

癌症治療

■ 產品/技術簡介

- 『人工智能』藥物研發模型，設計高潛力之小分子藥物。
- 『智慧合成』藥物合成策略，進行高效率之藥物合成。

■ 應用

- 從臨床資料庫中鑑別出與藥理及致病等相關之關鍵蛋白質標靶，目標針對這些標靶研發新穎藥物用以治療惡性神經膠母細胞瘤。


■ 優勢

- 目前之先導藥物在數種動物模型以口服方式給藥皆展現良好效果。
- 具有創新藥物研發專業，及兩項技術轉移與創立兩間新創公司之豐富經驗。

Sub-project 1

AI Platform

許凱程




**Novel Strategy
for Discovery of
Inhibitors
against GBM**

Sub-project 2

Smart Synthesis


謝興邦



Sub-project 3

Character Validation

潘秀玲



Novel Strategy for Discovery of Inhibitors against Glioblastoma

Research Area Cancer Treatment

Technical statement

- An artificial intelligence (AI) platform for designing inhibitors.
- A smart synthesis approach to efficiently and precisely synthesize a focused library.

Applications

- We have identified critical targets with important pharmacological and pathological roles in GBM tumor development by analyzing clinical data.


Advantages

- Current potential lead compounds showed potent *in vivo* efficacy by oral administration in several animal models.
- We have expertise with developing novel therapeutic drugs, and experience with twice technology transfer and launching two startup companies.

Sub-project 1

AI Platform

許凱程



**Novel Strategy
for Discovery of
Inhibitors
against GBM**

Sub-project 2

Smart Synthesis


謝興邦



Sub-project 3

Character Validation

潘秀玲



計畫主持人 Project PI 謝興邦 Hsing-Pang Hsieh



計畫成員 Member

Dr. 潘秀玲 Shioh-Lin Pan

Dr. 許凱程 Kai-Cheng Hsu

李昆鴻

李慕琄

陳怡穎

宋姿瑩



- Contact person: Dr. 謝興邦
- TEL: +886-2-7750-5500
- Email: alexhsieh@gate.sinica.edu.tw